{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004619","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.047373+00:00","generated_at":"2026-06-06T11:29:16.753256+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi Biotherapeutics raises $1M via convertible note with Ingodwe Trust","bullets":["Issued 12% simple interest one-year convertible promissory note for $1,000,000 principal.","Conversion at 10% discount to 10-day VWAP; optional warrant for 50% of conversion shares at 120% of conversion price.","Proceeds used for working capital; mandatory conversion if public offering occurs before maturity.","Lender Ingodwe Trust is an accredited investor; securities issued under Rule 506(b) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004619","json":"https://secwatch.observer/filing/0001493152-24-004619.json","markdown":"https://secwatch.observer/filing/0001493152-24-004619.md","text":"https://secwatch.observer/filing/0001493152-24-004619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/0001493152-24-004619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:29:16.753256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4b23ca55409d273131b0f5a1db50607932ce1b8","claim":"Calidi Biotherapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Accredited Investor (the Lender) valued at $1,000,000 (effective 2024-01-26).","evidence_excerpt":"On January 26, 2024, Calidi Biotherapeutics, Inc. (the “Company”) entered into a convertible promissory note purchase agreement (the “Purchase Agreement”) with an Accredited Investor (the “Lender”), for a loan in the principal amount of One Million dollars ($1,000,000), the proceeds of which will be used by the Company for working capital purpose (the “Loan”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/0001493152-24-004619-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Accredited Investor (the Lender)"},{"label":"Value","value":"$1,000,000"},{"label":"Effective","value":"2024-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}